Stephens Consulting’s 10x Genomics TXG Stock Holding History

Stephens Consulting’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$343	Hold	21	–	–	﹤0.01%	442
2025 Q3	$246	Hold	21	–	–	﹤0.01%	381
2025 Q2	$244	Hold	21	–	–	﹤0.01%	1027
2025 Q1	$184	Hold	21	–	–	﹤0.01%	1504
2024 Q4	$302	Hold	21	–	–	﹤0.01%	505
2024 Q3	$475	Buy	+21	New	+$434	﹤0.01%	498

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Consulting's TXG Position: Q4 2025 in Review

Stephens Consulting held its 10x Genomics (TXG) position steady in Q4 2025 at 21 shares worth $343. The position accounts for ﹤0.01% of the portfolio, ranked #442.

Stephens Consulting first reported a position in TXG in Q3 2024 and has held it in 6 quarters since. The position peaked at $475 in Q3 2024. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

Stephens Consulting held 21 shares of 10x Genomics worth $343 as of Q4 2025.
Stephens Consulting left its 10x Genomics share count unchanged in Q4 2025.
10x Genomics made up ﹤0.01% of Stephens Consulting's portfolio in Q4 2025, its #442 holding.
Stephens Consulting first reported a position in 10x Genomics in Q3 2024 and has held it in 6 quarters since.
Stephens Consulting's 10x Genomics position peaked at $475 in Q3 2024.
322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.